Evidence Grade E — Very limited evidence. 0 published studies. 0 registered clinical trials.
Medically reviewed by a licensed medical professional
CJC-1295 DAC is a long-acting version of CJC-1295 that binds to blood albumin, extending its effects to 6-8 days from a single injection. Its clinical development was abandoned after the developer went bankrupt. A death from heart attack occurred during clinical trials in 2006; causality was not established but the FDA required cardiac monitoring for subsequent studies. It has no regulatory approval.
CJC-1295 DAC is also known by these brand and alternate names:
No published studies found on PubMed.
CJC-1295 DAC has no marketing authorisation from any regulatory agency. Phase I data showed sustained growth hormone elevation over 6–8 days and IGF-1 elevation over 9–11 days following a single injection. A death from myocardial infarction occurred during clinical trials in 2006; causality was not established, but the FDA required cardiac monitoring protocols for subsequent studies. ConjuChem Biotechnologies entered bankruptcy in 2010 and no further clinical development has occurred.
No Phase III trials were completed. Products available through unregulated sources lack pharmaceutical quality assurance. The clinical trial death, unresolved safety questions, and absence of further development should be noted when assessing this compound.
Research suggests the same GHRH receptor mechanism as CJC-1295 (#89), but with sustained activity over 6–8 days due to albumin binding. A critical distinction is that this sustained stimulation produces continuously elevated growth hormone and IGF-1 levels rather than the pulsatile pattern seen with shorter-acting GHRH analogues. Research suggests non-pulsatile growth hormone elevation may differ pharmacologically from physiological growth hormone secretion.
Research suggests Phase I data showed sustained growth hormone and IGF-1 elevation lasting 6-8 and 9-11 days respectively after a single injection. No efficacy trials were completed before the developer's bankruptcy in 2010. A critical distinction from shorter-acting GHRH analogues is that the sustained stimulation produces continuously elevated (non-pulsatile) growth hormone — which differs fundamentally from the body's natural pulsatile pattern. Research suggests non-pulsatile growth hormone elevation may carry different risks including insulin resistance and fluid retention. Products from unregulated sources lack pharmaceutical quality assurance.
PeptideTrace tracks 0 registered clinical trials for CJC-1295 DAC sourced from ClinicalTrials.gov.
No trials registered on ClinicalTrials.gov for this compound.
CJC-1295 DAC is the Drug Affinity Complex version: modified GRF 1-29 covalently linked to MPA linker reacting with serum albumin in vivo. Extends half-life to ~6-8 days (vs. ~30 min without DAC). Unconjugated MW ~3,647 Da; albumin-conjugated ~70 kDa. Developed by ConjuChem Biotechnologies. Produces sustained (non-pulsatile) GH elevation.
Research suggests same GHRH-R mechanism as CJC-1295 without DAC. Critical difference: sustained agonism over 6-8 days produces continuously elevated GH/IGF-1 rather than pulsatile pattern. May cause greater GHRH-R tachyphylaxis. Non-pulsatile elevation resembles exogenous GH.
No marketing authorization. Phase I (Teichman, JCEM 2006; N=21): single SC 30-60 mcg/kg sustained GH elevation 6-8 days, IGF-1 1.5-3-fold for 9-11 days. Clinical trial death 2006 (MI; causality unestablished, FDA required cardiac monitoring). No Phase III. ConjuChem bankrupt 2010.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Compare prices from 15 vendor listings
View pricing data across vendors and countries for CJC-1295 DAC
Somatrogon is marketed as Ngenla (approved June 2023) for paediatric growth hormone deficiency in children aged 3 years and older. In the pivotal trial, once-weekly somatrogon produced growth rates equivalent to daily somatropin injections (10.1 cm/year versus 9.8 cm/year), confirming that reducing injection frequency does not compromise growth outcomes. Ngenla represents a meaningful advance for paediatric patients and their families, reducing injections from 365 to 52 per year. Treatment adherence has been a persistent challenge with daily growth hormone, and weekly dosing is expected to improve long-term outcomes through better compliance. Somatrogon competes directly with somapacitan (Sogroya), the other approved weekly growth hormone, creating a new generation of less burdensome treatment options.
Somapacitan is marketed as Sogroya (approved August 2020 for adult growth hormone deficiency; expanded April 2023 to paediatric growth hormone deficiency in children aged 2.5 years and older). It is the first once-weekly growth hormone approved for both adult and paediatric patients. In adults, clinical trials showed improvements in body composition including reduced truncal fat. In children, growth rates were comparable to daily somatropin. The albumin-binding approach provides predictable drug levels with lower peak-to-trough variation than some other long-acting growth hormone technologies. Sogroya competes with somatrogon (Ngenla) in the growing once-weekly growth hormone market, with both products expected to gradually replace daily injections as the standard of care.
ACE-031 has no marketing authorisation. A Phase I trial in healthy women showed increased lean mass and decreased fat mass. A Phase II trial in DMD (24 patients) showed lean body mass increases but was discontinued due to bleeding-related safety concerns (epistaxis, telangiectasias, and gum bleeding), likely caused by inhibition of BMP-9/10 vascular signalling. ACE-031 is a large fusion protein (~90 kDa), not a peptide. Its clinical development was halted. The non-selective ligand-trapping profile — capturing beneficial vascular signalling molecules alongside the intended muscle-growth targets — illustrates the challenge of targeting the TGF-beta superfamily. Acceleron subsequently developed more selective agents.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
